This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

AstraZeneca Lays Out Sales Targets to Fight Pfizer Bid

Stocks in this article: AZN PFE

LONDON (The Deal) -- The U.K.'s AstraZeneca (AZN - Get Report) said on Tuesday it wants to almost double revenue to at least $45 billion by 2023 as it launched its defense against Pfizer (PFE - Get Report) and its unwanted 63.1 billion pounds ($107.2 billion) bid.

The London pharmaceuticals company insisted it was headed back to a growth trajectory after patent expiries weighed on 2013 revenue and earnings. In February it reported 2013 revenue of $25.7 billion, a decline of 6%, with operating profit from its core business down 25%, at $8.4 billion. AstraZeneca on Tuesday predicted 2017 revenue would be "broadly in line" with the 2013 level.

"From 2017 to 2023 AstraZeneca is targeting strong and consistent revenue growth leading to annual revenues of greater than $45 billion by 2023. Operating leverage is expected to result in core earnings growth in excess of revenue growth during this period," the company added.

As it brought forward the anticipated timing of certain Phase II and Phase III trials, it also said it sees peak sales for pipeline products of about $63 billion, or $23 billion after adjusting for risk.

"AstraZeneca is completing its transformation, and now has the right size, focus and team to deliver on one of the most exciting pipelines in the pharmaceutical industry," said CEO Pascal Soriot in a statement.

Chairman Leif Johansson added that its independent strategy will provide " benefits that should fully accrue to AstraZeneca's shareholders."

AstraZeneca rejected a sweetened 5,000 pence-per-share, stock-heavy proposal from the New York maker of Viagra on Friday, arguing that it was both way too low and motivated by so-called tax inversion -- Pfizer wants to change its tax domicile to the U.K. to benefit from the country's lower corporate tax rate.

Pfizer, which is considering its options, has until May 26 to either make a firm offer, or announce its retreat.

The target's shares have held resolutely under the 5,000 pence level of its most recent proposal, reflecting some doubt that the takeover will happen. On Tuesday afternoon in London, AstraZeneca stock was down 130.50 pence, or 2.7%, at 4,677.50 pence.

As Pfizer's deliberations continue its bid has become a lightening rod for political concerns that Britain's "open" takeover regime leaves its companies vulnerable to asset stripping and its employees exposed. With a year to go before general elections, the opposition Labour Party has ridden to AstraZeneca's rescue, accusing the Conservative-Liberal Democrat government of acting as "cheerleaders" for the American bid.

AstraZeneca chairman Johansson on Friday urged Prime Minister David Cameron to take a neutral stance, the Financial Times reported on Monday, citing people familiar with the conversation.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.65 +225.28 1.31%
S&P 500 2,024.04 +21.88 1.09%
NASDAQ 4,686.8550 +48.8610 1.05%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs